Description: Nabriva Therapeutics AG, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which has completed a Phase II clinical trial for acute bacterial skin and skin structure infections. The company is developing intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia; and intends to develop lefamulin for additional indications other than pneumonia. It also develops BC-7013, a topical pleuromutilin antibiotic, which has completed a Phase 1 clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria.
Home Page: www.nabriva.com
NBRV Technical Analysis
25-28 North Wall Quay
Dublin,
1
Ireland
Phone:
353 1 649 2000
Officers
| Name | Title |
|---|---|
| Mr. Theodore R. Schroeder | CEO & Director |
| Dr. Steven P. Gelone Pharm. D | Pres, COO & Director |
| Dr. Colin Broom M.D. | Director |
| Mr. Daniel Dolan | Chief Financial Officer |
| Mr. J. Christopher Naftzger BA, Esq., J.D. | Gen. Counsel & Sec. |
| Ms. Jodi VanDerveer | Sr. VP & Head of HR |
| Mr. Gary L. Sender | Consultant |
| Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H. | Chief Medical Officer |
| Mr. Werner Heilmayer | VP of CMC & IP |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2392 |
| Price-to-Sales TTM: | 0.166 |
| IPO Date: | 2015-09-18 |
| Fiscal Year End: | December |
| Full Time Employees: | 73 |